TOP TEN perturbations for 39021_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39021_at
Selected probe(set): 212792_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39021_at (212792_at) across 6674 perturbations tested by GENEVESTIGATOR:
OPM-1 / MM1.S
Relative Expression (log2-ratio):-3.6401052Number of Samples:4 / 4
Experimental | OPM-1 |
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-resistant. Synonyms:OPM1 Cellosaurus code: | |
Control | MM1.S |
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-sensitive. Parental cell line:: MM.1 Synonyms:MM.1S; MM1-S; MM-1S; MM1S Cellosaurus code: |
ovarian tumor study 16 / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):-2.9882307Number of Samples:3 / 5
Experimental | ovarian tumor study 16 |
Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM). | |
Control | normal ovarian surface epithelial cell sample |
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue. |
breast cancer study 48 (PDX; metaplastic carcinoma, NOS; primary) / breast cancer study 48 (PDX; infiltrating duct carcinoma, NOS; primary)
Relative Expression (log2-ratio):2.7242355Number of Samples:8 / 60
Experimental | breast cancer study 48 (PDX; metaplastic carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary metaplastic carcinoma, NOS of the breast (subcutaneously implanted). | |
Control | breast cancer study 48 (PDX; infiltrating duct carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary infiltrating duct carcinoma, NOS of the breast (subcutaneously implanted). |
glioma study 16 (LN-229) / normal astrocyte sample
Relative Expression (log2-ratio):2.5392208Number of Samples:2 / 3
Experimental | glioma study 16 (LN-229) |
Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
stem cell differentiation study 59 (iDRG; 12d) / stem cell differentiation study 59 (8d)
Relative Expression (log2-ratio):-2.487854Number of Samples:4 / 4
Experimental | stem cell differentiation study 59 (iDRG; 12d) |
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper. | |
Control | stem cell differentiation study 59 (8d) |
WA09 embryonic stem cell samples differentiated for 8 days. Further details are described in the paper. |
sangivamycin study 1 / untreated MCF-7 cell sample
Relative Expression (log2-ratio):-2.4158363Number of Samples:2 / 2
Experimental | sangivamycin study 1 |
MCF7 cells treated with 2uM sangivamycin for 24 hours. ATC code:--- | |
Control | untreated MCF-7 cell sample |
MCF-7 cells untreated. |
myotonic dystrophy study 4 (deltoid muscle; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.4129438Number of Samples:3 / 3
Experimental | myotonic dystrophy study 4 (deltoid muscle; DM-like) |
Deltoid muscle biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
Control | normal skeletal muscle tisuue (fetal) |
Commercially purchased normal fetal skeletal muscle tissue samples. |
ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.4042034Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):2.3980293Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.390108Number of Samples:13 / 2
Experimental | ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |